Clinical Biochemistry - Copper Metabolism
Céruloplasmine | Clinique Omicron Québec
Ceruloplasmin is a plasma glycoprotein of the multicopper oxidase family, synthesized mainly by liver hepatocytes and to a lesser extent by testicular Sertoli cells and brain astrocytes. It is the main plasma copper transporter, carrying under normal conditions around 65 to 90 % of circulating copper in highly bound, non-exchangeable form. Each ceruloplasmin molecule incorporates six to eight copper atoms in its three-dimensional structure, on which its ferroxidase enzymatic activity depends - its ability to oxidize ferrous iron (Fe²⁺) to ferric iron (Fe³⁺), an essential step in the incorporation of iron into transferrin and its export from cells to the circulation. This dual function - copper transport and iron oxidation - makes ceruloplasmin a hinge protein between copper and iron metabolism, whose deficiency simultaneously disrupts the homeostasis of both essential metals. Its serum assay is prescribed mainly in two distinct clinical contexts: the diagnostic work-up of Wilson's disease, an autosomal recessive genetic disorder caused by a mutation in the ATP7B gene leading to toxic accumulation of copper in the liver, brain, kidneys and cornea, in which ceruloplasmin is lowered in over 80 % of cases; and the search for hereditary aceruloplasminemia, a complete ceruloplasmin deficiency caused by mutation of the CP gene, resulting in organ iron overload due to loss of ferroxidase activity. Ceruloplasmin also behaves as a positive acute-phase protein, whose levels increase in inflammatory syndromes, pregnancy and under the effect of estrogens, complicating its interpretation in these contexts and possibly masking an underlying deficiency.
Physiological role and biological functions
Ceruloplasmin performs several important biological functions that go beyond simple copper transport:
- Copper transport: it incorporates about 65 to 90 % of plasma copper in the form of cupric copper (Cu²⁺) tightly bound to its protein structure; unlike albumin, which transports copper loosely and exchangeably, copper bound to ceruloplasmin is not directly bioavailable to tissues and does not contribute to oxidative toxicity
- Ferroxidase activity (iron oxidase): its most clinically documented enzymatic function consists of catalyzing the oxidation of Fe²⁺ to Fe³⁺, allowing the incorporation of iron into transferrin and its transport to hematopoietic organs; in the absence of ceruloplasmin, iron accumulates in the macrophages of the liver, spleen, and brain in the form of non-transferable Fe²⁺
- Antioxidant properties: ceruloplasmin inhibits lipid peroxidation by scavenging free Fe²⁺, which would otherwise catalyze the Fenton reaction to produce highly toxic hydroxyl radicals; it thus constitutes an important plasma antioxidant defense.
- Oxidation of biological substrates: It oxidizes several biological substrates including catecholamines (adrenaline, dopamine), serotonin, and certain biogenic amines, contributing to their plasma degradation; its amine oxidase activity can be measured in the laboratory as an indirect marker of its enzymatic activity.
- Role in angiogenesis and cell differentiation: Experimental data suggest a role for ceruloplasmin in the regulation of angiogenesis and the differentiation of hematopoietic stem cells, which is still under study in humans.
Dosage instructions
Ceruloplasmin levels are indicated in specific clinical contexts, mainly related to copper and iron metabolism:
| Indication | Clinical context | Objective of the assay |
|---|---|---|
| Suspicion of Wilson's disease | Child or young adult (5 to 35 years old) with unexplained liver disease (chronic hepatitis, early cirrhosis, acute liver failure), neurological or psychiatric symptoms (tremors, dysarthria, behavioral disturbances, psychosis) with no other identified etiology | Low ceruloplasmin (< 0.20 g/L) is present in 80-95 % of homozygous Wilson's disease cases; it should be interpreted with serum copper, 24-hour urinary copper, and the presence of Kayser-Fleischer rings on slit-lamp examination |
| Family screening for Wilson disease | Siblings and children of a patient with confirmed Wilson disease; first-degree relatives are at a 25% % risk of being affected (autosomal recessive disease) | Early detection of presymptomatic Wilson's disease, allowing chelation therapy to be initiated before the onset of irreversible organ damage |
| Workup of unexplained liver disease | Any unexplained chronic hepatic cytolysis in a patient under 40 years of age after exclusion of common viral, metabolic, and autoimmune causes | Exclude Wilson's disease as an underlying cause; Wilson's disease can mimic autoimmune hepatitis, NASH, or cirrhosis of another origin. |
| Suspicion of hereditary aceruloplasminemia | Adult with a triad of diabetes, retinal degeneration, and neurological syndrome (ataxia, dysarthria, abnormal movements) with hyperferritinemia and microcytic anemia. | Undetectable or near-zero ceruloplasmin (< 0.02 g/L); confirms complete ceruloplasmin deficiency due to CP gene mutation; very rare disease, autosomal recessive inheritance |
| Assessment of an atypical iron overload | Hyperferritinemia with elevated transferrin saturation coefficient without identified HFE mutation, or hepatic iron overload with anemia | Exclude aceruloplasminemia as a cause of functional iron overload (iron accumulated in macrophages without being mobilizable); the biological profile is distinct from classic hereditary hemochromatosis |
| Menkes syndrome (infant) | Male infant with severe hypotonia, seizures, hair abnormalities (twisted hair, pili torti), and severe developmental delay from the first months of life. | Very low ceruloplasmin with collapsed serum copper and urinary copper; X-linked syndrome due to ATP7A gene mutation (distinct from ATP7B gene involved in Wilson's disease) leading to a copper intestinal absorption deficiency |
ℹ️
Ceruloplasmin is a positive acute-phase protein: its level increases by 50 to 100 % during an inflammatory syndrome, pregnancy, or estrogen intake (oral contraception, hormone replacement therapy). A normal or slightly elevated ceruloplasmin level in a patient with Wilson's disease and concomitant inflammation may therefore mask the expected deficiency and distort the diagnostic interpretation. In this context, measuring CRP and 24-hour urinary copper is essential to avoid missing the diagnosis.
Reference values and interpretation thresholds
The normal ranges for ceruloplasmin vary by age, sex, and the patient's physiological state. The thresholds below correspond to values commonly used in Quebec and Canadian laboratories:
| Population | Normal range (g/L) | Interpretation |
|---|---|---|
| Adult (male and female) | 0.20 – 0.60 g/L | Normal range; does not rule out Wilson's disease if concomitant inflammation; to be interpreted with serum and urinary copper |
| Pregnant woman or on estrogen | Up to 0.80 – 1.00 g/L | Physiological elevation of hepatic synthesis due to estrogenic stimulation; may mask a deficiency in a pregnant Wilson's disease patient; interpretation is delicate in this context |
| Infant (0 to 6 months) | 0.02 – 0.10 g/L | Physiologically low values at birth, gradually increasing with age; neonatal levels do not rule out Wilson's disease at this age, which generally does not manifest before 5 years of age |
| Child (6 months – 12 years) | 0.15 – 0.50 g/L | Rates progressively increasing until adulthood; adult values serve as reference from puberty |
| Lowered — suspected deficiency | less than 0.20 g/L | Suggestive of Wilson's disease, Menkes syndrome, or severe protein malnutrition; essential further investigation: serum copper, 24-hour urinary copper, slit-lamp ophthalmological examination, complete liver function tests, liver biopsy if necessary |
| Very low to undetectable | Less than 0.05 g/L | Highly suggestive of hereditary aceruloplasminemia (complete deficiency) or severe Wilson's disease; genetic analysis of the CP gene (aceruloplasminemia) or ATP7B (Wilson's) depending on the clinical context |
Wilson's Disease: Diagnosis and the Role of Ceruloplasmin
Wilson's disease is the disease for which ceruloplasmin levels have the most important diagnostic value. Understanding its mechanisms helps interpret the biological result:
- Wilson's disease is caused by mutations in the ATP7B gene (chromosome 13q14), which codes for a copper-transporting ATPase expressed in hepatocytes. This protein is responsible for the biliary excretion of excess copper and its incorporation into ceruloplasmin. In the absence of normal protein function, copper accumulates in the liver, then spills into the blood in free form and deposits in target organs.
- Ceruloplasmin is lowered in Wilson's disease for two complementary reasons: reduced hepatic synthesis secondary to hepatocellular damage, and especially a lack of copper incorporation into ceruloplasmin during synthesis, leading to the production of an apoprotein (apoceruloplasmin) that is rapidly catabolized in circulation.
- Ceruloplasmin is lowered (< 0.20 g/L) in 80 to 95 % of homozygous Wilson's disease cases; however, 5 to 20 % of Wilson's patients have normal ceruloplasmin levels, which does not allow the diagnosis to be excluded on this criterion alone.
- Conversely, low ceruloplasmin is not pathognomonic of Wilson's disease; it is also observed in severe hepatocellular insufficiency of any cause (global hepatocyte destruction), protein-calorie malnutrition, Menkes syndrome, and hereditary aceruloplasminemia.
- The Leipzig score, used for the diagnosis of Wilson's disease, incorporates ceruloplasmin, Kayser-Fleischer rings, 24-hour urinary copper excretion, liver copper on biopsy, genetic testing results, and neurological and hepatic clinical manifestations; a score of ≥ 4 is diagnostic, 3 is probable, and ≤ 2 is unlikely.
- L'anneau de Kayser-Fleischer — dépôt de cuivre visible à l'examen à la lampe à fente à la périphérie de la cornée — est présent dans plus de 95 % des formes neurologiques et 50 à 65 % des formes hépatiques pures ; son absence n'exclut pas le diagnostic, mais sa présence chez un patient jeune avec hépatopathie et céruloplasmine basse est hautement évocatrice
Causes of ceruloplasmin abnormality
Ceruloplasmin can be decreased or elevated in many clinical situations that should be known for rigorous interpretation:
| Anomaly | Cause | Mechanism and clinical context |
|---|---|---|
| Low ceruloplasmin | Wilson's Disease | Defective incorporation of copper into hepatic ceruloplasmin due to ATP7B mutation; rapidly catabolized apoceruloplasmin; reference genetic cause of low ceruloplasmin in children and young adults |
| Low ceruloplasmin | Severe hepatocellular insufficiency | Global reduction in hepatic protein synthesis (albumin, clotting factors, ceruloplasmin) in any decompensated cirrhosis, fulminant hepatitis, or severe acute liver failure regardless of cause |
| Low ceruloplasmin | Severe protein-energy malnutrition | Deficit in protein substrates for hepatic synthesis; observed in severe malabsorption, chronic malnutrition, nephrotic syndrome (urinary protein loss). |
| Low ceruloplasmin | Hereditary aceruloplasminemia | Complete ceruloplasmin deficiency due to mutation of the CP gene; accumulation of iron in the liver, pancreas, and brain due to loss of ferroxidase activity; clinical triad: diabetes, retinal degeneration, neurological syndrome |
| Low ceruloplasmin | Menkes syndrome | X-linked copper transport defect; intestinal copper absorption and transport defect; collapsed serum copper and ceruloplasmin; severe neurological manifestations from early childhood |
| High ceruloplasmin | Acute or chronic inflammatory syndrome | Positive acute-phase protein synthesized in excess by the liver under the influence of IL-6 and IL-1; increases in all inflammation, infection, trauma, active neoplasia |
| High ceruloplasmin | Pregnancy and exogenous estrogens | Direct estrogen stimulation of hepatic ceruloplasmin synthesis; levels can double in the third trimester of pregnancy or with combined oral contraception. |
| High ceruloplasmin | Primary biliary cirrhosis (primary biliary cholangitis) | Copper accumulation in the liver secondary to chronic cholestasis with biliary copper retention; paradoxically associated with normal or elevated ceruloplasmin, unlike Wilson's disease. |
| High ceruloplasmin | Hereditary hemochromatosis HFE | Moderate elevation possible as an inflammatory protein in response to iron overload; non-specific |
Additional assessment of copper metabolism
Ceruloplasmin levels cannot be interpreted in isolation and are part of a comprehensive copper metabolism assessment that includes several complementary tests:
- Total serum copper: measures all circulating copper (bound to ceruloplasmin + free exchangeable copper); decreased in Wilson's disease due to reduced cupric ceruloplasmin, but free copper (unbound to ceruloplasmin) is paradoxically increased and toxic
- Serum free copper (copper not bound to ceruloplasmin): calculated by the formula—free copper = total copper (µg/dL) - [3.15 × ceruloplasmin (mg/dL)]; a value above 25 µg/dL is suggestive of Wilson's disease; represents the biologically active and potentially toxic fraction of circulating copper
- 24-hour urine copper (urinary copper): reflects the load of free, exchangeable copper filtered by the kidneys; a value greater than 100 µg/24 hours (> 1.6 µmol/24 hours) in a symptomatic patient strongly suggests Wilson's disease; the D-penicillamine loading test (administration of 500 mg of D-penicillamine before and 12 hours after the start of collection) increases sensitivity in children
- Liver biopsy with intrahepatic copper measurement: reference method for the diagnosis of Wilson's disease; hepatic copper greater than 250 µg/g dry weight is pathognomonic (normal value < 50 µg/g); also evaluates the degree of fibrosis and liver histological damage
- Slit lamp examination: search for Kayser-Fleischer rings (brownish-green ring at the periphery of the cornea) and sunflower cataracts, characteristic of Wilson's disease.
- Genetic analysis of the ATP7B gene: sequencing of the gene for pathogenic mutations; more than 600 mutations described; useful for confirming the diagnosis in dubious cases and for screening asymptomatic carrier relatives; a single identified mutation without a second mutated allele is not sufficient to exclude the diagnosis due to frequent compound heterozygosity
ℹ️
The diagnosis of Wilson's disease is often delayed by several years due to the wide variability of its clinical presentations. It can manifest as apparent autoimmune hepatitis, cryptogenic cirrhosis, isolated psychiatric disorders (depression, anxiety, psychosis), or neurological symptoms (tremors, dystonia, dysarthria) in an adolescent or young adult. Any presentation of unexplained chronic liver disease before the age of 40 or any unexplained neuropsychiatric syndrome in a patient under 35 years of age warrants a ceruloplasmin level measurement in the initial workup.
Sample collection procedure and analytical precautions
Ceruloplasmin is measured using a simple blood sample, but a few precautions optimize the reliability of the result:
- Standard venipuncture in a serum tube (red or gold top); no fasting required, although fasting is generally recommended for standardized conditions.
- Inform the prescribing physician of any ongoing inflammatory conditions (infection, inflammatory flare-up, recent surgery), pregnancy, or estrogen intake, as these situations elevate ceruloplasmin and can mask a deficiency. In these contexts, CRP should be measured simultaneously to correctly interpret the result.
- Ceruloplasmin dosage must be performed concurrently with total serum copper and 24-hour urinary copper for a complete assessment of copper metabolism; ceruloplasmin alone has insufficient diagnostic value for Wilson's disease.
- Avoid blood draws in the weeks following a blood transfusion or albumin infusion, as these therapies can alter measured plasma protein levels.
- The result is usually available within 24 to 72 hours; 24-hour urinary copper measurement requires a specific 24-hour collection in a metal-free container provided by the laboratory.
- The most widely used assay methods are immunonephelometry or immunoassay; oxidase activity can also be measured as a functional alternative to immunological assay, with comparable performance for Wilson disease screening.
Treatment of Wilson's disease
Wilson's disease is a treatable and potentially curable disease if diagnosed before organ damage becomes irreversible. Ceruloplasmin is used as a marker for therapeutic monitoring:
| Treatment | Mechanism of action | Indications and follow-up |
|---|---|---|
| D-penicillamine | Copper chelator forming a soluble complex excreted in the urine; reduces the pool of toxic free circulating and tissue copper | Historical first-line treatment; demonstrated efficacy but limited tolerability profile (hypersensitivity reactions, nephrotoxicity, autoimmune effects, initial paradoxical neurological worsening in 10 to 20 % of cases); monitoring by copper excretion and ceruloplasmin every 3 to 6 months |
| Trientine (triethylenetetramine) | Copper chelating agent, mechanism similar to D-penicillamine but less copper chelated per molecule; better neurological tolerance | Alternative to D-penicillamine, particularly recommended in cases of intolerance or neurological worsening under D-penicillamine; first-line treatment in some North American practice guidelines for neurological forms |
| Zinc salts | Induce the synthesis of intestinal metallothioneins that scavenge dietary copper and prevent its absorption; reduce accumulation without chelating already accumulated copper | Maintenance treatment once copper depletion has been achieved by chelation; first-line treatment for presymptomatic forms and maintenance during pregnancy (established safety); monitoring by urinary copper and zinc excretion |
| Liver transplantation | Replacement of the diseased liver with a healthy, functional liver restoring normal copper excretion and normal ceruloplasmin synthesis; definitive curative treatment | Indicated in cases of fulminant acute liver failure of Wilson's disease not responding to medical treatment, or end-stage Child-Pugh C cirrhosis; corrects hepatic manifestations but the impact on pre-existing neurological manifestations varies depending on their degree of reversibility. |
Situations requiring immediate medical evaluation
In a child or young adult under 35 years of age with unexplained liver disease (jaundice, elevated transaminases, early-onset cirrhosis), progressive neurological or psychiatric symptoms with no obvious cause, or Coombs-negative hemolytic anemia associated with liver signs, a ceruloplasmin level and copper studies should be performed without delay to rule out Wilson's disease. Acute liver failure in an adolescent or young adult with hemolytic anemia should immediately suggest Wilson's disease in relapse and constitutes a hepatological emergency requiring referral to a specialized center for evaluation for emergency liver transplantation.
For any ceruloplasmin abnormality or suspicion of copper metabolism disorder, a consultation at Clinique Omicron allows for a structured medical evaluation and referral to specialized hepatology or metabolic genetics resources at one of our service points in Quebec or via telemedicine. To book an appointment, visit cliniqueomicron.ca.
Consult at Clinique Omicron
Clinique Omicron provides prescription and interpretation of biological copper metabolism assessments, including ceruloplasmin levels, at its service points in Quebec and via telemedicine. A physician or nurse practitioner (NP) can analyze your results within their clinical context, prescribe necessary additional tests (serum copper, urinary copper, liver function tests), and coordinate referral to a hepatologist, neurologist, or medical geneticist as needed. To book an appointment at one of our service points or via telemedicine, visit cliniqueomicron.ca.
The content of this page is for informational purposes only and does not substitute for the advice of a qualified healthcare professional. Consult a doctor for any abnormal biological results, unexplained hepatic or neurological symptoms, or decisions regarding your health.
Omicron Clinic
Need to consult a doctor?
Treatment within 24-48 hours. In-clinic or telemedicine, anywhere in Quebec.
Insurance receipts. 7j/7. No family doctor required.